26 results about "Eisosome assembly" patented technology

IMPROVED PROMOTERS AND COMPOSITIONS 5 The present invention relates to activatable promoters, as well as expression systems, vectors, delivery systems, reaction vessels, aqueous objects and compositions comprising said activatable promoters. The invention also provides compositions comprising assemblies and networks of aqueous objects comprising said activatable promoters. The invention additionally provides methods of expressing a transcript and methods of expressing a 10 polypeptide using the activatable promoters of the invention. The invention further provides phospholipid mixtures, as well as aqueous objects and compositions comprising said phospholipid mixtures.20 23 25 83 91 01 N ov 2 02 3 A B S T R A C T N o v 2 0 2 3 I M P R O V E D P R O M O T E R S A N D C O M P O S I T I O N S 2 0 2 3 2 5 8 3 9 1 0 1 1 0

The invention relates to a Sebastes schlegeli endogenous retrovirus envelope protein Penv, a lentiviral vector and application thereof, and belongs to the field of genetic breeding of molecular biology, and the amino acid sequence of the envelope protein Penv is as shown in SEQ ID NO.1. The invention further provides an in-vitro assembly system, a transformant and a kit containing membrane fusion protein particles and lentiviral particles of the envelope protein Penv and application of the envelope protein Penv. VSVG protein is replaced with Penv protein from sclerobone fish, so that the transduction efficiency of the lentiviral particles to sclerobone fish cells is effectively improved, and the transduction efficiency of the lentiviral particles to the sclerobone fish cells is improved. And efficient gene delivery is realized. Meanwhile, as the endogenous Env protein, the Env protein overcomes the immunological rejection of a host to the exogenous Env protein, and also has the potential of in-vivo application.

The invention discloses an electrochemical sensor for glycoprotein detection and a glycoprotein detection method. The method comprises the following steps: anchoring an aptamer-protein conjugate on the surface of a gold electrode, and then assembling an anti-fouling peptide around the aptamer-protein conjugate to form an imprinted self-assembled monolayer film. And removing the combined protein through an acid solution to form a biocompatible imprinting cavity capable of being used for recombining a target object. The imprinted cavity can eliminate non-specific adsorption and enhance targeted binding efficiency. The sensor can be used for directly detecting carcino-embryonic antigens with the concentration as low as 0.1 ng / mL through an electrochemical impedance spectroscopy method. Besides, homodimer concanavalin A (ConA) is used as a recognition element and a cross-linking agent, homodimer glucose oxidase (GOx) is assembled on the surface of the electrode in situ, a protein network can be formed, and enzyme catalysis signal amplification detection is achieved. Through in-situ formation of a ConA-GOx assembly, the sensitivity is improved by 100 times.

The application discloses a CAR-NK cell based on a dendritic molecule and a preparation method and application thereof. The CAR-NK cell is an assembly formed by the dendritic molecule, effectively loads nucleic acid expressing CAR through electrostatic interaction, forms a stable and uniform delivery system with nanometer size, is safely and effectively delivered to NK cells by virtue of the dendritic molecule, and prepares the CAR-NK cell with high-efficiency target gene expression, so as to solve the problems of low NK cell transduction efficiency and safety of a virus vector and improve the curative effect of the CAR-NK cell. The use of the dendritic molecule for transfection does not affect the phenotype of the NK cell and surface activation and inhibition receptors thereof. The CAR-NK cell prepared based on the dendritic molecule has a remarkable target cell killing efficiency in vitro and a remarkable anti-tumor (Raji-Luc transplanted tumor model) effect in vivo.

The present disclosure includes bioorthogonal conjugation systems and methods of producing same. The systems include at least one ncAA that participates in an orthogonal click reaction owing to its reactive group. The system further includes at least one plasmid having a gene for one or more of: an aminoacyl-tRNA synthetase, a tRNA, and a nanobody. Each nanobody includes suppression stop codons that define locations for conjugation of a ncAA, such that reactive groups of the ncAAs are incorporated at each defined location of the nanobody. Locations are not restricted to N and C terminals of the peptide, facilitating nanobody functionality post-conjugation. Resulting nanobodies are modified with the reactive groups of the ncAA in one or more locations, such that multiple cargos can be conjugated to each nanobody. Additionally, nanobodies can be conjugated to other nanobodies having corresponding reactive groups to form assemblies, which may be used as therapeutic nanobody libraries.

The application discloses a preparation method of fluorine-containing Fe3O4 nano-assemblies and application of the fluorine-containing Fe3O4 nano-assemblies in intracellular protein delivery, and the preparation method comprises the following steps: preparing Fe3O4 nanoparticles and small-molecule ligands containing fluorine alkyl chains respectively, and the two are combined through ligand exchange reaction to form fluorine-containing Fe3O4 nanoparticles; the fluorine-containing Fe3O4 nanoparticles can be self-assembled with proteins to form stable complexes through the hydrophobic effect and electrostatic effect of the fluorine alkyl chains. The fluorine-containing Fe3O4 assemblies provided by the application have universality as intracellular protein delivery carriers, can effectively deliver proteins with different isoelectric points and molecular weights to tumor cells, do not affect the biological activity of the cargo proteins, have small toxicity to cells, and have good biocompatibility. The protein delivery efficiency of the assemblies is further improved under the guidance of an external magnetic field, so that the killing effect of therapeutic proteins on tumor cells is enhanced, and the assemblies have application potential in the field of tumor treatment.

A method is provided for making a protein blocking assembly that is formed by reversibly linking a therapeutic protein to a crosslinking material. The protein blocking assembly contains a chemical structure, which is formed between the multiple bonds between the protein and the crosslinking material, that prevents the interaction of the protein blocking assembly with a second protein due to steric and / or static interference. Furthermore, administration methodologies of administering the protein blocking assembly to a subject are provided, where the protein is cleaved from the protein blocking assembly during or after administration.

The invention discloses a protein degradation agent based on an endosome-phagosome connection assembly and application of the protein degradation agent, and belongs to the technical field of protein degradation and nano biological medicine. According to the endosome-phagosome connecting assembly, by inserting an endosome membrane and marking endosome degradation protein, a special degradation technology strategy enables the endosome-phagosome connecting assembly to expand an autophagy degradation target spectrum in traditional cytoplasm to various target proteins outside a cell membrane / cell, and the current development situation of a current targeted protein degradation tool can be thoroughly changed possibly. The preparation method is simple, raw materials are easy to obtain, the method is suitable for research and application transformation, the traditional degradation thought is broken through by utilizing an endosome-phagosome connecting assembly, most target proteins can be degraded through an endosome-autophagy-lysosome approach, the design is novel, the application range is wide, the cost is low, the efficiency is high, a very good degradation effect can be achieved, and the method is suitable for popularization and application. The method can be applied to the field of various complex diseases and has huge potential development and transformation prospects.

The invention belongs to the technical field of biological medicine and nano delivery, and particularly relates to a supramolecular assembly as well as a preparation method and application thereof. The supramolecular assembly constructed by the invention is based on mediation of a polyphenol molecular adhesive, the polyphenol molecular adhesive can generate relatively strong interaction with a target protein, so that the surface of the target protein is modified with a catechol group, and the catechol group on the surface of the target protein can be combined with a functional polypeptide modified with a phenylboronic acid group; dynamic chemical bonds are formed through catechol and phenylboronic acid, a compound beneficial to endocytosis of cells is formed, and therefore the binding problem of cationic polypeptide and target protein is solved. According to the invention, the functional polypeptide modified with phenylboronic acid is constructed by utilizing the principle, and a nano-scale supramolecular assembly is formed by virtue of multiple interaction synergistic driving of the polyphenol molecular adhesive and the target protein, so that an efficient, universal and safe new scheme is provided for intracellular delivery of protein drugs.

The present disclosure includes bioorthogonal conjugation systems and methods of producing same. The systems include at least one ncAA that participates in an orthogonal click reaction owing to its reactive group. The system further includes at least one plasmid having a gene for one or more of: an aminoacyl-tRNA synthetase, a tRNA, and a nanobody. Each nanobody includes suppression stop codons that define locations for conjugation of a ncAA, such that reactive groups of the ncAAs are incorporated at each defined location of the nanobody. Locations are not restricted to N and C terminals of the peptide, facilitating nanobody functionality post-conjugation. Resulting nanobodies are modified with the reactive groups of the ncAA in one or more locations, such that multiple cargos can be conjugated to each nanobody. Additionally, nanobodies can be conjugated to other nanobodies having corresponding reactive groups to form assemblies, which may be used as therapeutic nanobody libraries.

The present application relates to a kind of Sebastes schlegelii endogenous retrovirus envelope protein P_env, lentivirus vector and its application, belong to the genetic breeding field of molecular biology, the amino acid sequence of the envelope protein P_env is as shown in SEQ ID NO.1.The present application simultaneously provides the membrane fusion protein plasmid of containing the envelope protein P_env, the in vitro assembly system of lentivirus particle, transformant and kit, and the application of the envelope protein P_env, the P_env protein of the present application is replaced VSVG protein using hard fish source, will effectively improve the transduction efficiency of lentivirus particle to hard fish cell, realize efficient gene delivery.Meanwhile, as endogenous Env protein, overcome the immune rejection of host to exogenous Env protein, also have the potential of in-vivo application.

The present invention relates to a nanoparticle, comprising an assembly of bacterial encapsulin protein monomers, and a protein located inside the nanoparticle, wherein the protein is a dimer or tandem-enzyme wherein each enzyme of the dimer or tandem is fused to at least one terminal targeting peptide (TP). The invention further relates to nanoparticles comprising modified encapsulin proteins, and methods and uses of the nanoparticles in medicine, industry, cleaning and biotechnology.

The invention belongs to the field of biological medicine, and particularly discloses a polypeptide co-assembly probe based on double-targeting design and a preparation method and application of the polypeptide co-assembly probe based on the double-targeting design, polypeptide FAM-GFFE-SQDIRTWNGTRS (FAM-P47) and polypeptide FAM-GFFK-NSATYKC (FAM-NP) are induced through a self-assembly motif GFF to form the double-targeting polypeptide co-assembly probe FAM-NP-P47; a net interwoven by nanofibers is formed on the surfaces of cells, so that more sensitive and accurate specific recognition is realized, strong-signal fluorescence is emitted on the surfaces of circulating tumor cells CTCs, excellent fluorescence detection performance is presented, and CTCs fluorescence imaging detection with high sensitivity and high signal-to-noise ratio can be realized through a simple method in a complex biological environment; the polypeptide sequence has the advantages of easiness in synthesis, good biocompatibility, customizable design, modularization and the like.

The present invention relates to a molecular assembly which is a novel axitinib polymorph in which axitinib is physically bound.

The application discloses synthesis of a protein polymer self-assembly with multiple environmental stimulus responsiveness and application thereof. Compared with common electrically neutral ELPs, the application finds that the negative electrically modified polymer carrier ELPs are not easy to be taken up by cells and metabolically removed in vivo, have longer drug half-life and bioavailability, and obviously improve pharmacokinetic characteristics; compared with traditional cationic nanoparticles, the negative electrically modified polymer carrier ELPs reduce cytotoxicity caused by positive charges, increase stability, and are easy to realize selective enrichment at an inflammation site, improve drug bioavailability and the like due to in-situ accumulation of part of inflammatory positive charges. The application also adds an MMP9 enzyme recognition site to the hydrophilic end of the ELPs, increases drug release and distribution at the inflammation site, and improves drug efficacy.

Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII).

This invention discloses a protein degrader based on an endosome-phagosome linker assembly and its applications, belonging to the fields of protein degradation and nanobiomedicine. The endosome-phagosome linker assembly can degrade proteins by inserting into the endosome membrane and labeling endosomes. Its unique degradation strategy expands the target spectrum of traditional intracellular autophagy degradation to include multiple target proteins on the cell membrane / extracellularly, potentially revolutionizing the current development of targeted protein degradation tools. The preparation method of this invention is simple, the raw materials are readily available, and it is suitable for research and application transformation. Utilizing the endosome-phagosome linker assembly breaks with traditional degradation approaches, achieving the degradation of most target proteins through an "endosome-autophagy-lysosome" pathway. The novel design has a wide range of applications, is low-cost, and highly efficient, demonstrating excellent degradation effects and potential for application in various complex disease areas, showing great development and translational prospects.

The present invention relates to an assembly for extracellular secretion of a target chemical substance, which comprises a conjugate including an aptamer fused to RNA of the target chemical substance that can be produced intracellularly, and a transporter including an RNA-binding protein fused to a carrier protein; a gene construct encoding each of the transporter and the conjugate constituting the assembly; a vector carrying the gene construct; a host cell into having the vector introduced thereinto; a method for producing the target chemical substance, the method comprising a step of culturing the host cell; an extracellular secretion system of the target chemical substance constructed by introducing the gene construct or the vector into a microorganism; and a method for producing the target chemical substance by activating the system. By using the assembly and the system according to the present invention, it is possible to increase the intracellular production as well as extracellular secretion and excretion of the target chemical substance, and the invention can be advantageously applied to the production of microorganism-based useful chemical substances.

This invention relates to a HER2-targeted antitumor peptide nanomedicine, its preparation method, and its applications. The antitumor peptide nanomedicine comprises an antitumor functional unit, a self-assembly unit, and a targeting unit connected in sequence; the targeting unit includes a peptide sequence targeting the HER2 protein. Through a specially designed peptide sequence, the peptide nanomedicine can be delivered to the lesion site via an active targeting mechanism based on molecular recognition. It then specifically binds to the HER2 target, achieving in-situ self-assembly at the tumor site. The resulting assembly exhibits a significant tumor-killing effect, and its preparation cost is low, demonstrating advantages and significant application prospects in targeted diagnosis and treatment of tumors.

An in-situ membrane protein dimerization state detection kit and the use thereof. The kit comprises a membrane protein anchor chain, a recognition probe and a SERS tag. Catalytic hairpin assembly is triggered by means of adjacent hybridization of the membrane protein anchor chain, which carries an adaptor sequence, during membrane protein dimerization to form a networked assembly of the recognition probe and the SERS tag, thereby performing SERS detection and imaging on a highly specific event in a cell communication process, namely the membrane protein dimerization. The kit is suitable for high-sensitivity monitoring of intercellular signaling based on membrane protein dimerization in a complex cell microenvironment.

This invention relates to chimeric peptide assemblies and methods for their preparation and use, specifically to bispecific chimeric peptide assembly compositions comprising a filling portion connected to a binding domain via a cleavable release segment. When the cleavable release segment is cleaved, it enables effector T cells to simultaneously bind to a targeted tumor or cancer cell, resulting in cell lysis of the tumor or cancer cell. The invention also provides compositions and methods for preparing and using the said cleavable chimeric peptide assembly compositions.

The application provides an enzymatic polypeptide self-assembly for targeting HER2 protein degradation and an application thereof, and relates to the technical field of biological medicines.The enzymatic polypeptide self-assembly for targeting HER2 protein degradation has the functions of enzyme catalytic cascade activation and enhancement of imaging and targeting HER2 protein degradation.The enzymatic polypeptide self-assembly material organically integrates the imaging unit and the treatment unit into the same carrier, avoids bringing additional physical burden to organisms, and has a good synergistic effect on intuitively and accurately revealing the targeting efficiency of polypeptide compounds targeting tumor cell membrane proteins and improving the accuracy of tumor targeted treatment, solves the problems of low membrane protein degradation efficiency and insufficient targeting in the prior art, provides a new strategy for precise tumor treatment, and has important clinical conversion value and application prospect.

Disclosed herein are nanostructures and their use, where the nanostructures include(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; andwherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

The invention relates to the technical field of rapid detection, and particularly discloses a construction method of a nano-enzyme colorimetric-magnetic relaxation dual-mode immunosensor based on sum, and the construction method comprises the following steps: step S01, preparation; step S02, preparation is carried out; s03, Ab <-> combined with the antibody is obtained and defined as a solution C; s04, Ag <-> combined with the antigen is obtained and defined as a solution D; step S05: self-assembly: mixing and incubating the solution C containing Ab <-> and the solution D containing Ag <-> to form a self-assembled body. The invention aims to provide a dual-mode immunosensor which is used for quickly and accurately identifying kitchen recovered oil, so that the problems of insufficient accuracy, high false negative and false positive rate and the like in a traditional single-mode sensing method are solved.

To provide subunit vaccines with nanostructure-based vaccines.SOLUTION: Provided herein are nanostructures and their use, where the nanostructures include: a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1 and I53_dn5A.2, or variants thereof; and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides being I53_dn5B or a variant thereof; where the first assemblies non-covalently interact with the second assemblies to form a nanostructure; and where the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof.SELECTED DRAWING: None

The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.